NeurAxis (NRXS) announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation, PENFS, is now in effect, completing a successful commercial milestone for the Company. The assignment of the Category I CPT code is one of the “most significant breakthroughs in efforts towards widespread adoption of IB-Stim,” the company said. This establishes a permanent, nationally recognized coding and billing pathway for NeurAxis’ PENFS therapy, reflecting broad clinical acceptance and meeting the American Medical Association’s, AMA, criteria for widespread utilization, clinical efficacy, and established standards of care.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXS:
